Ropes & Gray Represents Teva in Partnership with Samsung Bioepis to Commercialize Rare Disease Biosimilar in U.S.

Ropes & Gray represented Teva Pharmaceutical Industries in a license, development and commercialization agreement with Samsung Bioepis for rare disease therapy EPYSQLI, the biosimilar to Solirisi in the U.S. The deal was announced on January 10. Financial terms were not disclosed.

Under the agreement, Samsung Biopis will be responsible for the development, regulatory registration, manufacture and supply of the product. Teva will be responsible for commercialization of the product in the U.S.

The collaboration will enable Teva to leverage its extensive commercial capabilities and introduce a new biosimilar to its portfolio, increasing access to affordable treatments.

The Ropes & Gray team was led by life sciences licensing partner Abigail Gregor and life sciences licensing associate Zachary Kramer.